Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

NCT04918823 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Ocular Surface Disease

Interventions

DRUG: Restasis

Sponsor

Boston Sight

Collaborators

[object Object]